Cargando…
Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies
SIMPLE SUMMARY: Immunotherapies and molecularly targeted therapies have drastically changed the therapeutic approach for unresectable advanced or metastatic melanoma. The majority of melanoma patients have benefitted from these therapies; however, some patients acquire resistance to them. Novel comb...
Autores principales: | Rager, Taylor, Eckburg, Adam, Patel, Meet, Qiu, Rong, Gantiwala, Shahina, Dovalovsky, Katrina, Fan, Kelly, Lam, Katie, Roesler, Claire, Rastogi, Aayush, Gautam, Shruti, Dube, Namrata, Morgan, Bridget, Nasifuzzaman, S M, Ramaswami, Dhruv, Gnanasekar, Varun, Smith, Jeffrey, Merchant, Aftab, Puri, Neelu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367420/ https://www.ncbi.nlm.nih.gov/pubmed/35954441 http://dx.doi.org/10.3390/cancers14153779 |
Ejemplares similares
-
Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021) -
Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022) -
PRMT-1 and p120-Catenin as EMT Mediators in Osimertinib Resistance in NSCLC
por: Racherla, Kavya Sri, et al.
Publicado: (2023) -
Oligonucleotides and microRNAs Targeting Telomerase Subunits in Cancer Therapy
por: Eckburg, Adam, et al.
Publicado: (2020) -
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015)